Karen Carey

Arena Forms Deal Worth Up To $612M With Ortho-McNeil

Dec. 22, 2004

Arena Pharmaceuticals Inc. takes a case-by-case approach when it comes to partnering its drug candidates. If the economics are right, the San Diego-based company will sign on the dotted line. (BioWorld Today)

Cardiome Drug Hits Endpoint In Atrial Fibrillation Phase III

Dec. 21, 2004

By Karen Carey

Eyeing Cancer Drugs, Aphton Acquiring Igeneon For $81M

Dec. 16, 2004

By Karen Carey

Aphton Corp. entered a definitive agreement to acquire the privately held Vienna, Austria-based company Igeneon AG for more than $81 million in equity. (BioWorld Today)

Corixa Sells Bexxar To GSK, Cuts Staff By 160 Employees

Dec. 15, 2004

By Karen Carey

With slower-than-expected sales growth of Bexxar, Corixa Corp. decided to turn worldwide rights for the non-Hodgkin's lymphoma product over to partner GlaxoSmithKline plc. (BioWorld Today)

Protein-Misfolding Company FoldRx Gets $16M In Series A

Dec. 14, 2004

By Karen Carey

Osteologix Expands Overseas, Advances Bone Disease Drug

Dec. 13, 2004

By Karen Carey

With $62M Offering, Array Can Push More Into Clinic

Dec. 10, 2004

By Karen Carey

NitroMed, Preparing For BiDil Launch, Publicly Raises $80M

Dec. 9, 2004

By Karen Carey

Positive Phase III results for its heart failure drug BiDil certainly played a role in NitroMed Inc.'s ability to raise almost $80 million in a public offering on Wednesday. (BioWorld Today)

Micromet, Serono Enter Cancer Drug Deal Worth Up To $148M

Dec. 8, 2004

By Karen Carey

In a deal just shy of $150 million, Micromet AG partnered with Serono SA its Phase II monoclonal antibody, MT201, designed to treat prostate and metastatic breast cancer. (BioWorld Today)